Hansoh Pharma's Ametinib Secures Over $1 Billion Global Licensing Deal with Glenmark
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
On December 16, Hansoh Pharma announced that it had entered into an agreement with Glenmark Specialty S.A. regarding Ameletinib.Exclusive License, Collaboration and Distribution Agreement。
Source of screenshot: Corporate announcement
According to the license agreement, Hansoh Pharma will grant Glenmark an exclusive license, allowing it to operate in the authorized region.(Middle East and Africa, Southeast Asia and South Asia, Australia, New Zealand, Russia and other CIS countries, as well as certain specific Caribbean countries covered by the agreement)Develop and commercialize Ameitinib.
In return, Hansoh Pharma will receive an upfront payment and potential subsequent cumulative payments.More Than One Billion US DollarsRegulatory and commercial milestone payments, as well as tiered royalties on net sales within the licensed territory.
Almonertinib isChina's First Original Third-Generation EGFR-TKI Innovative Drug，Has been approved for four indications in China, respectively:
In March 2020, it was approved for patients with locally advanced or metastatic NSCLC who had progressed after prior EGFR-TKI treatment and were positive for the T790M mutation;
In December 2021, it was approved as a first-line treatment for adult patients with locally advanced or metastatic NSCLC who have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations;
In March 2025, it was approved for the treatment of patients with unresectable locally advanced NSCLC with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations who did not experience disease progression after platinum-based radical chemoradiotherapy.
In May 2025, it was approved for the treatment of adult patients with Stage Ⅱ-ⅢB NSCLC harboring EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. Patients must have previously undergone surgical resection and may receive or not receive adjuvant chemotherapy as determined by their physician.
In addition, in June 2025, Ameitinib(UK product name Aumseqa®)Awarded by the UK Medicines and Healthcare products Regulatory Agency（MHRA）Approved for marketing.
